RxDoctor Payments Data

Kenneth Neal, MD

MOHS-Micrographic Surgery · Arlington, VANPI 1881629590

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $7,600 of the $8,757 with a category attached, or 86.8%. Sun Pharmaceutical Industries Inc. accounts for 96.6% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $5,297 and has fallen 99.3% since, to $37 in 2024. Among mohs-micrographic surgery clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,757in general payments, 2019–2025

Across 29 payments — averaging $301.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$8K
  • Amgen$182
  • Taro Pharmaceuticals USA, Inc.$31
  • E.r. Squibb & Sons, L.L.C.$19
  • Convatec Inc.$19
  • Mission Pharmacal Company$17
  • plus $29 from 2 others

What the payments were for

  • Speaking & faculty fees$7,60087%
  • Travel & lodging$7659%
  • Food & beverage$3924%

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,757 in reported general payments places this provider in the 90th percentile of 36 mohs-micrographic surgery providers in Virginia.

See all mohs-micrographic surgery providers in Virginia

Medicare billing

Part B allowed, 2024
$1,533,285
Medicare patients
320
Services billed
1,977

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast11$53,138
Desoximetasone28$5,690
Fluocinonide73$3,134
Desonide47$2,781
Naftifine Hcl12$2,776
Clobetasol Propionate22$2,195
Tretinoin22$1,715
Clindamycin Phosphate37$1,654
Azelaic Acid21$1,443
Betamethasone Valerate21$915
Metronidazole13$736
Cephalexin60$524
Ketoconazole32$475
Minocycline Hcl13$311
Triamcinolone Acetonide19$208

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$182$53,13811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 36 mohs-micrographic surgery providers in Virginia.

Other mohs-micrographic surgery in Arlington

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →